-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the process of exploring the treatment of diabetes , many large studies have found that intensive hypoglycemia can control blood sugar levels for a long time, and reduce the risk of patients with macrovascular and microvascular complications and diabetes-related end events
Diabetic blood vessels
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and dipeptidyl peptidase-4 (DPP-4) inhibitors may increase the risk of intestinal obstruction, but there is no real evidence of this serious adverse event
Therefore, the purpose of this study was to determine whether GLP-1 RA and DPP-4 inhibitors are associated with an increased risk of intestinal obstruction compared with sodium-glucose cotransporter-2 (SGLT-2) inhibitors
Experimental method experimental method
We use the UK clinical practice research data link and link database to assemble two new user, active control cohorts (2013-2019)
Experimental results
Experimental results Experimental resultsCompared with SGLT-2 inhibitors, GLP-1 RA is associated with an increased risk of intestinal obstruction (1.
Compared with SGLT-2 inhibitors, GLP-1 RA is associated with an increased risk of intestinal obstruction.
Conclusion conclusion
In this large real-world study, GLP-1 RA and DPP-4 inhibitors were associated with an increased risk of intestinal obstruction
In this large real-world study, GLP-1 RA and DPP-4 inhibitors were associated with an increased risk of intestinal obstruction
Original link: https://pubmed.
Original link: https://pubmed.
2021 Sep 29.
doi: 10.
1002/cpt.
2430.
Leave a message here
